# Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

> **Open Intelligence Dossier** · First detected: 2026-09-21 15:00 UTC · Category: Business

## Executive Summary
Telix's $2.35 billion merger with ITM signals a bold move into radiopharmaceuticals, drawing analyst optimism.

## Intelligence Brief
Telix announced a merger with radioisotope maker ITM, valuing the transaction at up to US$2.35 billion. The deal is framed as a bid to create a ‘radiopharmaceutical powerhouse’ and to expand Telix’s portfolio beyond its existing pharmaceutical offerings. Coverage indicates the transaction will bring together Telix’s drug development capabilities with ITM’s expertise in radioisotope production, positioning the combined entity to compete in a market traditionally dominated by larger firms. Law.com reported that HSF Kramer and Sidley Austin are advising Telix on the deal, while Latham &amp;amp; Watkins LLP disclosed that it is advising ITM.


Endpoints News echoed the financial terms and highlighted the strategic intent behind the merger. BioPharma Dive focused on the ambition to build a radiopharmaceutical leader, emphasizing the scale of the transaction and the potential for synergies between the two companies. The consistent mention of legal advisors across the four sources underscores the complexity and regulatory scrutiny typical of high‑value biotech mergers. The next phase will involve regulatory clearance in the jurisdictions where both companies operate, as well as the integration of research, manufacturing, and commercial functions.


Market participants will watch for formal statements from the companies on timeline expectations, and for any early analyst commentary on projected revenue impact. Further reporting from the cited outlets is expected as the merger progresses through antitrust review and post‑deal integration planning.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Law.com | HSF Kramer, Sidley Austin Advise Telix on $2.35B Pharma Deal | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxPZDBjd0s3Y3pMU3N6MVhuUng2TFNadlZSVFNMbjVrMnV0ZGFRNGNmLTlGbUVaRTNjZF9uSTVJTkxzN1pJNDVrNmFfa3Z3S19pYk5ncW44SHpQcmp4cVJrVmJXdWd1Z3l3dWVPNlhmX09tVXE4NElwNHlOdVpHS0VhYkEyUmZ2WEJmRGJhOWpBQmJtQXNFOWprSlBvV0pMTmZCMmFTTVBqSEZBRUFnTkdyVA?oc=5) |
| BioPharma Dive | Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’ | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxNbE82aWllZlJpNmVuN3VjNWhMTEpzMkVteXBzcThIaUYzNlpvVUZLNmhCdnpuR21hTHREVHZPTmhqVWhoSnRvUmFRdVhqQUZPSUVMbDhMOGJRUEMtdnF2YUFlbkZYblZ3VUtoM2V5Q29QWklVaDFsSGZpQ0ItTm9xaXBmTnFwa1I1Q2U5RlJ6azc4NGhnNHJJSnZOeTJIQkNfeV9idXo0bw?oc=5) |
| Latham & Watkins LLP | Watkins Advises ITM in Merger With Telix Valued at Up to US$2.35 Billion | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxQOUEzcmJBV0U4THFQRzNLT2lOS2xXRXU3VVF5ak9wajBRa2JJcm9kbWJQU0JjNlZYbi1GcU9YMllYbzc1bTEzYjJkaG52cUZLMU9rYnFQNjlXSExEVzZlVUJZazVFMjBZR0VqVGtPcUV3aEtyZUV6MEc4RHBCZll2RGRLanJPb1lwMXc?oc=5) |
| Endpoints News | Telix and radioisotope maker ITM merge in deal worth up to $2.35B | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxOcHp3dmNSamRTaTE4cC12ZnFTbnhMdTN5WTRqVGl0SjlyeTZwTFV3cE1WVFdKbVM4NTFPaFgxcDV0UE0ybWNob3hDaEgyOU5TRDV3ZE1jbDBLOVhzNk9xbnRkYUZGbXlhS3RjZ0U5cklqY21UdkhKSG5EZUZFVVlhU1hELWFaR2lDSG5kcHc2ckxlQQ?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-09-21/analysts-extremely-bullish-as-telix-beams-into-novartis-territory-with-1-6b-itm*
